| 1 |
Silencing of microRNAs in vivo with ‘antagomirs’
Jan Krützfeldt, Nikolaus Rajewsky, Ravi S Braich et al. · Nature
|
30 Oct 2005 |
3,987 |
| 2 |
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David H Adams et al. · New England Journal of Medicine
Open access |
4 Jul 2018 |
3,046 |
| 3 |
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thomas Thum et al. · Nature
|
30 Nov 2008 |
2,368 |
| 4 |
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek et al. · Nature
|
Nov 2004 |
2,191 |
| 5 |
Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters
Markus Feuerer, Laura Herrero, Daniela Cipolletta et al. · Nature Medicine
Open access |
26 Jul 2009 |
2,160 |
| 6 |
Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter
Joshua M. Baughman, Fabiana Perocchi, Hany S. Girgis et al. · Nature
Open access |
17 Jun 2011 |
1,960 |
| 7 |
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al. · Nature Biotechnology
|
17 Jan 2010 |
1,819 |
| 8 |
Plasma proteomic associations with genetics and health in the UK Biobank
Benjamin B. Sun et al. · Nature
Open access |
4 Oct 2023 |
1,716 |
| 9 |
Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape
Jérôme Gilleron, William Querbes, Anja Zeigerer et al. · Nature Biotechnology
|
23 Jun 2013 |
1,660 |
| 10 |
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc, Martin A. Maier, Muthiah A. Manoharan et al. · Nature Nanotechnology
Open access |
Dec 2019 |
1,651 |
| 11 |
RNAi-mediated gene silencing in non-human primates
Tracy S. Zimmermann et al. · Nature
|
26 Mar 2006 |
1,355 |
| 12 |
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui et al. · Angewandte Chemie International Edition
Open access |
10 Jul 2012 |
1,268 |
| 13 |
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc et al. · Molecular Therapy
Open access |
11 May 2010 |
1,263 |
| 14 |
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc et al. · Nature Biotechnology
Open access |
27 Apr 2008 |
1,238 |
| 15 |
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Veit Hornung, Margit Guenthner‐Biller, Carole Bourquin et al. · Nature Medicine
Open access |
20 Feb 2005 |
1,235 |
| 16 |
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles, Hans-Peter Vornlocher, John M. Maraganore et al. · Nature Reviews Drug Discovery
ReviewOpen access |
Jun 2007 |
1,204 |
| 17 |
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
Kiran Musunuru et al. · Nature
Open access |
Aug 2010 |
1,204 |
| 18 |
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Hyukjin Lee, Abigail K. R. Lytton‐Jean, Yi Chen et al. · Nature Nanotechnology
Open access |
Jun 2012 |
1,180 |
| 19 |
miR-181a Is an Intrinsic Modulator of T Cell Sensitivity and Selection
Qi-Jing Li, Jacqueline Chau, Peter Ebert et al. · Cell
Open access |
23 Mar 2007 |
1,160 |
| 20 |
Multivalent N -Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al. · Journal of the American Chemical Society
|
Dec 2014 |
1,126 |
| 21 |
RNAi therapeutics: a potential new class of pharmaceutical drugs
David A. Bumcrot, Muthiah A. Manoharan, Victor Koteliansky et al. · Nature Chemical Biology
Open access |
15 Nov 2006 |
1,091 |
| 22 |
MicroRNAs 103 and 107 regulate insulin sensitivity
Mirko Trajkovski, Jean Hausser, Jürgen Soutschek et al. · Nature
Open access |
Jun 2011 |
995 |
| 23 |
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Christian Wolfrum, Shuanping Shi, K. Narayanannair Jayaprakash et al. · Nature Biotechnology
|
16 Sep 2007 |
982 |
| 24 |
Lipid-like materials for low-dose, in vivo gene silencing
Kevin T. Love, Kerry P. Mahon, Christopher G. Levins et al. · Proceedings of the National Academy of Sciences
Open access |
11 Jan 2010 |
982 |
| 25 |
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al. · New England Journal of Medicine
Open access |
28 Aug 2013 |
981 |
| 26 |
Chemistry, structure and function of approved oligonucleotide therapeutics
Martin Egli, Muthiah A. Manoharan · Nucleic Acids Research
Open access |
7 Mar 2023 |
851 |
| 27 |
Therapeutic siRNA silencing in inflammatory monocytes in mice
Florian Leuschner et al. · Nature Biotechnology
Open access |
9 Oct 2011 |
847 |
| 28 |
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin J. Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine
Open access |
13 Nov 2016 |
773 |
| 29 |
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep M. Tabernero et al. · Cancer Discovery
|
28 Jan 2013 |
709 |
| 30 |
Origins of tumor-associated macrophages and neutrophils
Virna Cortez‐Retamozo, Martin Etzrodt, Andita Newton et al. · Proceedings of the National Academy of Sciences
Open access |
30 Jan 2012 |
702 |
| 31 |
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Anders Wittrup, Angela Ai, Xing Liu et al. · Nature Biotechnology
Open access |
20 Jul 2015 |
693 |
| 32 |
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria D. Frank-Kamenetsky et al. · Proceedings of the National Academy of Sciences
Open access |
11 Aug 2008 |
647 |
| 33 |
Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
Martin A. Maier et al. · Molecular Therapy
Open access |
25 Jun 2013 |
640 |
| 34 |
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Kathryn A. Whitehead, J. Robert Dorkin, Arturo J. Vegas et al. · Nature Communications
Open access |
27 Jun 2014 |
635 |
| 35 |
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani et al. · New England Journal of Medicine
Open access |
10 Jun 2020 |
617 |
| 36 |
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight
James E. Dahlman et al. · Nature Nanotechnology
Open access |
11 May 2014 |
590 |
| 37 |
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin J. Fitzgerald, Maria D. Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet
Open access |
3 Oct 2013 |
580 |
| 38 |
A viral microRNA functions as an orthologue of cellular miR-155
Eva Gottwein, Neelanjan Mukherjee, Christoph Sachse et al. · Nature
Open access |
Dec 2007 |
568 |
| 39 |
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda, Rudy Bonavia, Akitake Mukasa et al. · Genes & Development
Open access |
15 Aug 2010 |
549 |
| 40 |
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al. · New England Journal of Medicine
Open access |
31 Mar 2021 |
520 |
| 41 |
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
Barbara L. Mui, Ying K. Tam, Muthusamy Jayaraman et al. · Molecular Therapy — Nucleic Acids
Open access |
2013 |
504 |
| 42 |
MICU1 Controls Both the Threshold and Cooperative Activation of the Mitochondrial Ca2+ Uniporter
György Csordás, Tünde Golenár, Erin L. Seifert et al. · Cell Metabolism
Open access |
Jun 2013 |
500 |
| 43 |
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Yizhou Dong et al. · Proceedings of the National Academy of Sciences
Open access |
10 Feb 2014 |
492 |
| 44 |
Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing
Jens Harborth, Sayda M. Elbashir, Kim Vandenburgh et al. · Antisense and Nucleic Acid Drug Development
|
Apr 2003 |
476 |
| 45 |
MICU2, a Paralog of MICU1, Resides within the Mitochondrial Uniporter Complex to Regulate Calcium Handling
Molly Plovanich, Roman L. Bogorad, Yasemin Sancak et al. · PLoS ONE
Open access |
7 Feb 2013 |
476 |
| 46 |
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Scott David Solomon, David H Adams, Arnt V. Kristen et al. · Circulation
|
17 Jan 2019 |
465 |
| 47 |
Specificity, duplex degradation and subcellular localization of antagomirs
Jan Krützfeldt, Satoru Kuwajima, Ravi S Braich et al. · Nucleic Acids Research
Open access |
16 Apr 2007 |
459 |
| 48 |
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
John P. DeVincenzo, Rob Lambkin‐Williams, Tom M. A. Wilkinson et al. · Proceedings of the National Academy of Sciences
Open access |
26 Apr 2010 |
442 |
| 49 |
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Joseph D. Szustakowski et al. · Nature Genetics
111 authors |
28 Jun 2021 |
439 |
| 50 |
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation
Chai-Wan Kim, Carol Addy, Jun Kusunoki et al. · Cell Metabolism
Open access |
Aug 2017 |
425 |